New drug combo aims to shrink hard-to-treat tumors

NCT ID NCT04678648

First seen Jan 12, 2026 · Last updated Apr 28, 2026 · Updated 10 times

Summary

This early-phase study tests a new drug called RSC-1255, alone or with hydroxychloroquine, in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard treatments. The goal is to find a safe dose and see if the drug can control the disease. About 134 people will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sarah Cannon, SCRI Oncology Partners

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Sarah Cannon, SCRI Oncology Partners - Health One

    RECRUITING

    Denver, Colorado, 80218, United States

  • University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology

    RECRUITING

    Los Angeles, California, 90404, United States

Conditions

Explore the condition pages connected to this study.